文献速递腹部技术与安全CT

FOLFIRINOX 治疗后 CT 判断可切除性对临界可切除及不可切除胰腺导管腺癌的预测价值

CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
PubMed 文献 · Eur Radiol · 2020-08-26

可切除性分组间 R0 切除率无显著差异(67–73%,p=0.95),可切除性及可切除性变化预测 R0 的敏感度分别为 67% 和 80%、特异度分别为 37% 和 21%;与动脉接触的软组织低强化(≤46.4 HU)与 R0 切除独立相关(p=0.01)。

要点

  • 可切除性变化分组间 R0 切除率亦无显著差异(56–77%,p=0.39)。
  • 与动脉接触软组织强化程度 ≤46.4 HU 与 R0 切除独立相关(p=0.01)。

关键影像表现/征象

  • 可切除、临界可切除与不可切除组间 R0 切除率无显著差异(67–73%,p=0.95)。
  • 可切除性变化为消退、稳定与进展组间 R0 切除率无显著差异(56–77%,p=0.39)。

诊断标准与关键数值

  • 以可切除/临界可切除 vs 不可切除判断 R0 切除,敏感度 67%、特异度 37%。
  • 以可切除性变化消退/稳定 vs 进展判断 R0 切除,敏感度 80%、特异度 21%。
  • 与动脉接触软组织呈低强化(≤46.4 HU)与 R0 切除独立相关(p=0.01)。

临床应用与阅片要点

  • 关注与动脉接触软组织的强化程度,≤46.4 HU 时注意其与 R0 切除的关联。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We aimed to assess the ability of CT-determined resectability, as defined by a recent version of NCCN criteria, and associated CT findings to predict margin-negative (R0) resection in patients with PDAC after neoadjuvant FOLFIRINOX chemotherapy.

METHODS: Sixty-four patients (36 men and 28 women; mean age, 58.8 years) with borderline resectable or unresectable PDAC who received neoadjuvant FOLFIRINOX were evaluated retrospectively. CT findings were independently assessed by two abdominal radiologists according to NCCN criteria (version 3. 2019). Tumor resectability was classified as resectable, borderline resectable, or unresectable, and change in resectability was classified as regression, stability, or progression. The associations of R0 resection rate with CT-determined resectability and change in resectability categories were evaluated, as were the sensitivity and specificity of NCCN criteria for R0 resection. Factors associated with R0 resection were identified by logistic regression analysis.

RESULTS: R0 resection rate did not differ significantly among the resectable, borderline resectable, or unresectable PDAC (67-73%, p = 0.95) or among PDAC with regression, stability, or progression (56-77%, p = 0.39). The sensitivity and specificity for R0 resection were 67% and 37%, respectively, for resectability (resectable/borderline vs. unresectable) and 80% and 21%, respectively, for changes in resectability (regression/stable vs. progression). Low-contrast enhancement of soft tissue contacting artery (≤ 46.4 HU) was independently associated with R0 resection (p = 0.01).

CONCLUSION: CT-determined resectability after neoadjuvant FOLFIRINOX chemotherapy was relatively insensitive and non-specific for predicting R0 resection. Low-contrast enhancement of soft tissue contacting artery may increase the ability of CT to predict R0 resection.

KEY POINTS: • Margin-negative resection rate of pancreatic cancer following FOLFIRINOX therapy did not differ among each resectability (67-73%, p = 0.95) based on NCCN criteria or changes in resectability categories (56-77%, p = 0.39). • The sensitivity and specificity for margin-negative resection were 67% and 37% for resectability (resectable/borderline vs. unresectable) and 80% and 21% for changes in resectability (regression/stable vs. progression). • Low-contrast enhancement of soft tissue contacting artery (≤ 46.4 HU) was independently associated with margin-negative resection (p = 0.01).

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Jang JK, Byun JH, Kang JH, et al. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Eur Radiol. 2020. PMID: 32845389. doi:10.1007/s00330-020-07188-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。